电邮这篇文章 TARGET THERAPY FOR NON-SMALL CELL LUNG CANCER: COMPLETE RESPONSE TO CRIZOTINIB
- 作者: Gordeeva O.O.1, Meshcheryakov A.A1, Meshcheryakova N.A1
-
隶属关系:
- N.N. Blokhin Cancer Research Center
- 期: 卷 24, 编号 1-2 (2019)
- 页面: 27-31
- 栏目: Articles
- URL: https://journal-vniispk.ru/1028-9984/article/view/42968
- DOI: https://doi.org/10.18821/1028-9984-2019-24-1-2-27-31
- ID: 42968
如何引用文章
全文:
详细
In this article we demonstrate a clinical case of young patient with non-small lung cancer with ALK-translocation treated with crizotinib in the first line of therapy. This approach was associated with complete response and acceptable toxicity.
作者简介
Olga Gordeeva
N.N. Blokhin Cancer Research Center
Email: helga.stolz@yandex.ru
Medical Oncologist, chemotherapy department #3, N.N.Blokhin NMRCO, 115478, Moscow, Russian Federation 115478, Moscow, Russian Federation
A. Meshcheryakov
N.N. Blokhin Cancer Research Center115478, Moscow, Russian Federation
N. Meshcheryakova
N.N. Blokhin Cancer Research Center115478, Moscow, Russian Federation
参考
- Arteaga C.L. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin. Oncol. 2002; 29: 3-9.
- Paez J.G., Janne P.A., Lee J.C. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (Wash D C). 2004; 304: 1497-500
- Soda M., Choi Y.L., Enomoto M. et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007; 448 (7153): 561-6.
- Alice T. Shaw, Beow Y. Yeap, Mari Mino-Kenudson, et al. Clinical Features and Outcome of Patients With Non-Small-Cell Lung Cancer Who Harbor EML4-ALK. J Clin. Oncol. 27: 4 247-53.
- Ming Sound Tsao, Fred R. Hirsch, Yasushi Yatabe. IASLC atlas of ALK testing in lung cancer. 2013.
- Benjamin J. Solomon et al. First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer. N. Engl. J. Med. 2014; 371: 2167-77.
- Юкальчук Д.Ю. и др. Применение кризотиниба в терапии ALK-позитивного немелкоклеточного рака лёгкого. Эффективная фармакотерапия. Онкология, гематология и радиология. Спецвыпуск «Рак: расширяя возможности лечения». 2016; 8.
- Paik P.K., Drilon A., Fan P.D. et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov. 2015; 5: 842-9.
补充文件
